Company
LON:AREC
Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK.
124 stories · page 6 of 7
"AT278 has the potential to be the first, and potentially only, ultra-concentrated (500U/mL) yet ultra-rapid acting insulin,” said chief executive Sarah Howell
Archive
16 June 2022*A corporate client of Hybridan LLPDish of the dayJoiners:No Joiners Today.Leavers:No Leavers Today.What’s cooking in the IPO kitchen?LifeSafe Holdings, a fire safety technology business with innovative fire safety products, int
The partner will fund the initial development work and has the option to acquire the rights to the new proprietary formulations
AT278 delivers significantly accelerated absorption of insulin compared with gold standard treatment, NovoRapid, delegates at an industry conference will be told
The company raised £20mln in its flotation on AIM and ended the year with cash and cash equivalents of £18.3mln, up from £2.9mln a year earlier
It's a feast of household names next week and all are likely to have one thing on their mind - inflation
The CambridgeshireLive Business Awards celebrate and recognise the region's best business talent
The company already has a patent portfolio protecting its Arestat technology platform and its proprietary pipeline products, with 36 patent families
The company's Arestat reformulation technology is used to enhance existing pharmaceutical products while enhancing care
Transfer of the formulation will trigger a milestone payment to Arecor
Arecor chief executive Sarah Howell said: "We continue to expand the multiple potential applications of our innovative Arestat platform."
It is developing a ready-to-administer product for a leading global medical products company
The pharma group has developed Arestat, a technology platform that allows drugs to be delivered more easily into patients’ bodies
The EPO considered but dismissed an appeal filed by GlaxoSmithKline, upholding the patent as granted to Arecor
The pharma group is planning further clinical trials for its lead products
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
The in-content advertising company today announces a strategic partnership with Influential, the world's largest influencer marketing company.
AT278 achieved its primary goal of being 'non-inferior' to the gold standard treatment, while the results also suggested it may have cleared a major hurdle in the race to find a fast-acting concentrated insulin
The trial will compare AT247 with Novo Nordisk’s NovoRapid and Fiast
The company's Arestat technology platform has been developed to enhance the properties of therapeutic proteins, peptides and vaccines
